{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:02:19Z","timestamp":1794614539633,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["IIR ISCS 17739"],"award-info":[{"award-number":["IIR ISCS 17739"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","award":["ISR004823\/BE-72-RG-13"],"award-info":[{"award-number":["ISR004823\/BE-72-RG-13"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.annonc.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T14:40:02Z","timestamp":1748616002000},"page":"1058-1067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"B.","family":"Tombal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-6729","authenticated-orcid":false,"given":"A.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-4315","authenticated-orcid":false,"given":"R.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Isaacsson Velho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nol\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-4850","authenticated-orcid":false,"given":"F.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-8137","authenticated-orcid":false,"given":"T.","family":"Roumeguere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7760","authenticated-orcid":false,"given":"E.","family":"Bompas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1133-110X","authenticated-orcid":false,"given":"F.","family":"Gomez Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Skoneczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4947-0304","authenticated-orcid":false,"given":"K.","family":"Martins da Trindade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mavignier Carcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-3254","authenticated-orcid":false,"given":"F.","family":"Lecouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Coens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.annonc.2025.05.011_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.011_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review","volume":"87","author":"Francini","year":"2025","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.011_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.011_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.05.011_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.05.011_bib7","series-title":"presented at the EAU Annual Congress Paris 2024","isbn-type":"print","year":"2024","ISBN":"https:\/\/id.crossref.org\/isbn\/9789492671233"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.011_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.011_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2307\/2529759","article-title":"On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial","volume":"32","author":"Freedman","year":"1976","journal-title":"Biometrics"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.011_bib12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing Radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.05.011_bib14","unstructured":"European Medicines Agency. Xofigo - referral. Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xofigo. Accessed May 27, 2025."},{"issue":"10","key":"10.1016\/j.annonc.2025.05.011_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/(SICI)1097-0258(20000530)19:10<1319::AID-SIM490>3.0.CO;2-0","article-title":"Pros and cons of permutation tests in clinical trials","volume":"19","author":"Berger","year":"2000","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.annonc.2025.05.011_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx376.022","article-title":"Correlation and differences in effect sizes between progression free survival (PFS) and overall survival (OS) among PD-1 inhibitors","volume":"28","author":"Gyawali","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.011_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/cancers17030495","article-title":"The relationship between response rate and survival benefits in randomized immunotherapy studies","volume":"17","author":"Jain","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.annonc.2025.05.011_bib19","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/ijms20163899","article-title":"The mode-of-action of targeted alpha therapy radium-223 as an enabler for novel combinations to treat patients with bone metastasis","volume":"20","author":"Suominen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.annonc.2025.05.011_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jnci\/djz007","article-title":"Radium 223-mediated zonal cytotoxicity of prostate cancer in bone","volume":"111","author":"Dondossola","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.annonc.2025.05.011_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.011_bib22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s11864-023-01094-z","article-title":"The intersection of prostate cancer and hypertension: a call to action","volume":"24","author":"Dolmatova","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.05.011_bib23","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.05.011_bib24","article-title":"Commercial and business aspects of alpha radioligand therapeutics","volume":"9","author":"Ostuni","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.annonc.2025.05.011_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.011_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41391-020-0236-0","article-title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Shore","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:10Z","timestamp":1762319650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0923753425002030"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}